Khera Tanvi, Helfand Jordan, Kelly Lauren, Mueller Ariel, Shankar Puja, Marcantonio Edward R, Subramaniam Balachundhar
Center for Anesthesia Research Excellence, Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Front Pharmacol. 2022 Mar 22;13:803903. doi: 10.3389/fphar.2022.803903. eCollection 2022.
Delirium, an acute decline in attention and global cognitive dysfunction, occurs frequently following cardiac surgery and has been demonstrated to be significantly associated with cognitive dysfunction and reduced functional ability. In the DEXACET trial, we demonstrated a significant reduction in postoperative in-hospital delirium with intravenous (IV) acetaminophen when compared with placebo. In this analysis we examined whether this protective association also extended to 12 month cognitive and functional outcomes. This study was a prospective, randomized, placebo-controlled, triple-blinded, factorial design trial conducted at Beth Israel Deaconess Medical Center, approved by the IRB. In this trial, 120 older cardiac surgical patients were randomly assigned to receive either intravenous (IV) acetaminophen or placebo in addition to propofol or dexmedetomidine. Those receiving IV acetaminophen displayed a significant reduction in in-hospital delirium. We collected cognitive, mood and functional outcome data using the Montreal Cognitive Assessment, telephone version (T-MoCA), Geriatric Depression Scale (GDS) and the Basic and Instrumental Activities of Daily Living (ADLs, IADLs) at 1 month and 12 months after surgery. Of the 120 enrolled patients in the primary trial, 93 (77.5%) and 83 (69.2%) patients responded to assessments at 1 month and 12 months, respectively. No statistically significant differences in median T-MoCA scores were observed between acetaminophen and placebo groups at 1 month (18.0 vs.18.0, = 0.52) or 12 months (19.0 vs.18.0, = 0.62) following surgery. There were similarly no differences in GDS, ADLs or IADLs between treatment groups. Losses to follow-up limited the sample sizes and 10 of the 23 (45%) original study participants who had postoperative delirium were lost to follow up. Administration of intravenous acetaminophen was not associated with a difference in long term cognitive or functional status following cardiac surgery. Additional research on long-term outcomes following postoperative delirium with a larger sample size and improved cohort retention strategies will be needed to address this important area.
谵妄是一种注意力急性下降和整体认知功能障碍,在心脏手术后经常发生,并且已被证明与认知功能障碍和功能能力下降显著相关。在DEXACET试验中,我们证明与安慰剂相比,静脉注射对乙酰氨基酚可使术后住院期间的谵妄显著减少。在本分析中,我们研究了这种保护关联是否也适用于12个月时的认知和功能结局。本研究是在贝斯以色列女执事医疗中心进行的一项前瞻性、随机、安慰剂对照、三盲析因设计试验,已获机构审查委员会批准。在该试验中,120例老年心脏手术患者被随机分配,除丙泊酚或右美托咪定外,接受静脉注射对乙酰氨基酚或安慰剂。接受静脉注射对乙酰氨基酚的患者住院期间谵妄显著减少。我们在术后1个月和12个月使用蒙特利尔认知评估电话版(T-MoCA)、老年抑郁量表(GDS)以及日常生活基本和工具性活动(ADL、IADL)收集认知、情绪和功能结局数据。在最初试验的120例入组患者中,分别有93例(77.5%)和83例(69.2%)患者在1个月和12个月时对评估做出了回应。术后1个月(18.0对18.0,P = 0.52)或12个月(19.0对18.0,P = 0.62)时,对乙酰氨基酚组和安慰剂组之间的T-MoCA中位数得分无统计学显著差异。治疗组之间在GDS、ADL或IADL方面同样没有差异。失访限制了样本量,23例术后发生谵妄的原始研究参与者中有10例(45%)失访。心脏手术后静脉注射对乙酰氨基酚与长期认知或功能状态差异无关。需要对术后谵妄的长期结局进行更多样本量更大且改善队列保留策略的研究,以解决这一重要领域的问题。